Wantstats
Company ProfilePremium

GENFIT

Company Profile Analysis

Book DemoRegister Your Interest
ESOMAR 23 Corporate BadgeISO Certifications Badge
GENFIT - Healthcare showcase

Year Founded & Workforce

1999

170 Employees

Industry

Healthcare

Services

Blood-Based Biomarker Test
G

GENFIT Employee Contacts

3 verified contactsNames, job titles, seniority and locations

View Employee Contacts

GENFIT Overview

Company Headquarters: Loos, France

Founded: 1999

Workforce: ~170

Company Working: GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. The company is currently developing a non-invasive and easy-to-access blood-based IVD test to identify patients with NASH. Also, the company’s pipeline drug, Elafibranor is assessed under phase III clinical trial as a potential treatment for NASH. The company operates in only one segment, the research & development of innovative medicines. The company has its operational facilities in Lille and Paris, France, and Cambridge, Massachusetts, US.

Strategy

GENFIT aims to develop innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases. The company also focuses on value-based healthcare principles to drive global growth. GENFIT focuses on becoming a leading company in the field of liver disease diagnosis by entering into various strategic mergers and ventures.

Company Snapshot

$0.3M

Revenue

170

Employees

1999

Founded

Loos, France

Headquarters

SWOT Analysis

Strengths

  • Skilled workforce
  • Increasing globally presence

Weaknesses

  • Limited product portfolio comparted to well-established players

Opportunities

  • Mergers and acquisitions
  • New product developments

Threats

  • Changing competitive landscape

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateApproachDevelopment
January 2019AgreementGENFIT and LabCorp signed a licensing agreement to expand access to NIS4, an innovative diagnostic assay for NASH. With this, the company aims to strengthen its position in the NASH biomarkers market.

Product Offering

  • GENFIT
    • Blood-Based Biomarker Test

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

By Business Segment: Sales fell from USD 0.3 Mn in 2016 to USD 0.1 Mn in 2018.
GENFIT — By Business Segment
Series (USD Mn)201620172018
Sales0.30.10.1
R&D Expenditure35,062.858,709.679,037.7

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.

Get Contacts →